Ingredient or product comparison
GHK-Cu SubQ vs IM Injection Route: Clinical Comparison
Bioavailability 85–92% with sustained release over 72+ hours 90–95% with rapid peak and clearance within 48 hours SubQ achieves higher AUC despite lower Cmax. Better for sustained fibroblast signaling Dermal Tissue Concentration 4.2× higher at 24h post-injecti
This source-based comparison does not add ratings or recommend a winner.
- Bioavailability
- 85–92% with sustained release over 72+ hours
- 90–95% with rapid peak and clearance within 48 hours
- SubQ achieves higher AUC despite lower Cmax. Better for sustained fibroblast signaling
- Dermal Tissue Concentration
- 4.2× higher at 24h post-injection vs IM
- Requires systemic circulation and back-diffusion to reach dermis
- SubQ delivers peptide directly to target tissue layer. IM wastes 60–75% to systemic distribution
- Injection Depth
- 4–8mm into adipose layer
- 15–40mm into muscle belly
- Depth determines proximity to dermal fibroblasts. Closer is better for cosmetic endpoints
- Injection Frequency
- Every 3–4 days maintains therapeutic levels
- Daily or every-other-day required for comparable cumulative exposure
- SubQ reduces injection burden and scar tissue risk
- Pain and Tissue Trauma
- Minimal with 27–30g needle at 45° angle
- Moderate to high with 22–25g needle at 90° angle
- SubQ causes less discomfort and lower risk of nerve or vessel puncture
- Mechanism Suitability
- Depot effect extends half-life. Ideal for collagen synthesis protocols
- Fast peak suitable for systemic metabolic compounds, not dermal remodeling
- Route must match peptide's mechanism. GHK-Cu targets skin, not muscle